, Volume 10, Issue 5, pp 333-335
Date: 24 Jun 2010

Oral Disease-Modifying Therapies for Multiple Sclerosis: Are We There Yet?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Kappos L, Radue EW, O’Connor P, et al.; FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387–401.

Cohen JA, Barkhof F, Comi G, et al.: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402–415.

Rating

•Of importance.

Introduction

Current US Food and Drug Administration (FDA)-approved disease-modifying therapies (DMTs) for multiple sclerosis (MS) require either self-injection (the interferon-β products and glatiramer acetate) or intravenous infusion (natalizumab and mitoxantrone). MS patients and their physicians have long wanted an effective oral DMT. That wait soon may be over. Earlier this year, the results of phase 3 clinical trials of two oral immunosuppressants for MS, fingolimod (AKA FTY720) and cladribine, were published, and both agents were found to be effective [13]. FDA approval of these oral agents for the treatment of MS will be a historic landmark in M